3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Mycosis Fungoides
3
Multiple Myeloma
3
Neoplasms, Plasma Cell
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Advanced Cancers
1
Interventions
Pemetrexed
4
Cisplatin
4
tislelizumab
1
rilotumumab
1
regorafenib
1
pembrolizumab
1
defactinib
1
atezolizumab
1
Vorinostat
1
Trioxsalen
1
Tomography, Optical Coherence
1
Photochemotherapy
1
Paclitaxel
1
LMB-100
1
Gemcitabine
1
Dihematoporphyrin Ether
1
Cytoreduction Surgical Procedures
1
Cryotherapy
1
Carboplatin
1
1-phenyl-3,3-dimethyltriazene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Mesothelioma, Malignant
×
Vorinostat
×
Clear all
NCT01353482
2012-03-22
MESO-02
University College, London
Phase 1/2
Withdrawn